Staging of patients with early pancreatic cancer is inaccurate as much as 80% of the time, according to a new Cedars-Sinai Cancer study published in the peer-reviewed journal JAMA.
Federal judge rules against Regeneron’s attempt to halt Amgen from launching Eylea biosimilar
Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS
September 25, 2024